We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Sygnature Discovery Announces Multi-Target Drug Discovery Deal with Sitryx Therapeutics

News   Nov 09, 2018

 
Sygnature Discovery Announces Multi-Target Drug Discovery Deal with Sitryx Therapeutics
 
 
 

RELATED ARTICLES

Strategy Could Help Treat Behavioral Abnormalities Linked to Autism

News

Researchers report in Nature Medicine a potential new treatment strategy for autism spectrum disorder – for which many cases are linked to mutated PTEN. Now, using Pten-deficient mice, researchers discover that a previously unexplored pathway goes “awry” in the brain, and by “rescuing” this pathway, it is possible to reverse behavioral and neurophysiological abnormalities.

READ MORE

Ebola Vaccine Could Stretch Farther

News

A new study has identified that a single dose of a highly diluted Ebola vaccine still fully protected against disease in a monkey model.

READ MORE

Ranitidine Recalled Due to Potential Carcinogen Contamination

News

Teva UK Ltd is recalling unexpired stock of certain batches of two types of Ranitidine medicines – used to treat conditions such as heartburn and stomach ulcers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Proteomics & Metabolomics Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE